News

FDA accepts Milestone's response on Cardamyst nasal spray, sets new PDUFA date; company raises $52.5 million to support ...
The Food and Drug Administration (FDA) has accepted for review Milestone’s response to issues raised in a Complete Response Letter (CRL) for etripamil nasal spray (Cardamyst ™ ), an investigational ...
A new study shows that oxytocin nasal spray helps mothers with postpartum depression interact more positively with their babies.
New PDUFA Action Date of December 13, 2025 $75 Million Royalty Purchase Agreement Payment from RTW Extended Through 2025 MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® ...
Researchers at Radboud University and the Radboudumc found that mothers with postpartum depression benefit from oxytocin ...
People with hay fever could one day benefit from a first-of-its-kind “molecular shield” that blocks pollen from entering the ...
ARS Pharmaceuticals' Neffy, an epinephrine nasal spray, is poised as a game-changer for emergency allergies, driving growth.
A mid-stage trial of BPL‑003 nasal spray shows promising results for treatment-resistant depression, igniting biotech ...
A psychedelic nasal spray requiring a much shorter period of clinical supervision has shown promise against ...
Lupin launches Ipratropium Bromide nasal spray for treating runny nose in the US market. Available in 0.03% and 0.06% ...
Ipratropium bromide nasal solution (Nasal Spray) 0.03% is indicated for the symptomatic relief of rhinorrhea associated with ...
New Opportunities will be offering a free “Be Prepared” presentation to assist in identifying and how to respond to an opioid overdose. On July 18 at the Audubon Rec Center Community Room, New Opportu ...